Interview, Fireside Chat
Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution
Sequoia CapitalMatthew Rabinowitz, Roelof Botha, Jonathan Sheena, Steve Chapman, Chitra Kotwaliwale, Sarah Elliot, Rolof Buerta
- The company aims to solve gaps in prenatal diagnostics by applying signal processing and Bayesian optimization to separate maternal, paternal, and fetal DNA, enabling the detection of genetic abnormalities in cell-free DNA from maternal blood as early as nine weeks of gestation.
- Early plans focused on the IVF market, which was assessed as a $600 million opportunity based on 160,000 annual US cycles, but the strategy pivoted to the broader prenatal testing market where the goal is to serve all pregnant women rather than just the 15% high-risk segment.
- The Panorama test became the most widely used prenatal test in America, shifting from a few hundred thousand to over one million annual samples, while Signatera entered the minimal residual disease (MRD) market for solid tumors, growing from 5,000 samples annually in 2019 to over 100,000 in Q1 2024.
- Financial projections indicate a company revenue of approximately $1.5 billion for the current year, with Signatera now utilized by 50% of US oncologists for bladder, colon, breast, and ovarian cancers, and monitoring for all solid tumor types.
- Future outlooks predict another order of magnitude in growth, with plans to leverage large language models and AI to curate data for predicting disease susceptibility and detecting cancer recurrence roughly a year before clinical symptoms appear.
- Strategic initiatives include changing the lab testing experience to resemble consumer e-commerce with transparency and billing updates, and expanding into women's health carrier screening alongside existing offerings.
- Risks identified include the challenge of creating new markets which venture capital often views warily, the threat of competitors launching updated products, and the survival pressure faced after a competitor was acquired by a major industry player.
- The company faces ongoing challenges in scaling operations, managing a shift from startup to mid-sized company status with rapid hiring, and maintaining an agile innovation culture to stay ahead of new players in women's health and oncology.